Quantitation of erbB2 positivity for evaluation of high-risk patients

References

• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12.
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmont C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–12.
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene 1991; 6: 137–43.
   PubMed Web of Science ®Google Scholar
• Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochetnical assay of p53, nm 23, erbB-2, and cathepsin D protein. J Surg Oncol 1997; 65: 22–7.
   PubMedGoogle Scholar
• Jalava PJ, Collan YUT, Kuopio T, Juntti-Patinen L, Kronqvist P. Bcl-2 immunostaining: A way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res 2000; 20: 1213–20.
   PubMedGoogle Scholar
• Shak A. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER-2-overexpres-sing metastatic breast cancer. Herceptin MultinationalInves-tigator Study Group. Semin Oncol 1999; 26 (4 Suppl 12): 71–7.
   PubMedGoogle Scholar
• Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001; 37 Suppl 1: S18–24.
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 15: 783–92.
   Web of Science ®Google Scholar
• Van der Vijver MJ. Assessment of the need and appropriate method for testing the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37: S11–7.
   PubMedGoogle Scholar
• Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et aL Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer re-fractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–71.
   PubMed Web of Science ®Google Scholar
• Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in diagnostic setting. Mod Pathol 2001; 14: 677–85. 13, Borresen A-L, Ottestad L, Gaustad A, Andersen TI,
   PubMed Web of Science ®Google Scholar
• Heikkild R, jahnsen T, et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990; 62: 585–90.
   PubMedGoogle Scholar
• Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive cancer. Hum Path ol 1992; 23: 974–9.
   PubMed Web of Science ®Google Scholar
• Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of HER-2/neu amplification and over-expression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 15: 1141–6.
   Google Scholar
• Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000; 5: 199–207.
   PubMedGoogle Scholar
• Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di-Leo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correla-tion with oncogene amplification in 160 cases. Am J Clin Pathol 2000; 113: 675–82.
   PubMed Web of Science ®Google Scholar
• Wang S, Saboorian MH, Frenicel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000; 53: 374–81.
   PubMed Web of Science ®Google Scholar
• Bankfalvi A, Simon R, Brandt B, Burger H, Vollmer I, Dockhorn-Dworniczak B, et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000; 37: 411–9.
   PubMedGoogle Scholar
• Taylor C, Shi S, Chaiwun B, Young L, Imam S, Cote R. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formali-paraffin sections: androgen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki-67 antigen revealed by antigen retrieval techniques. Hum Path ol 1994; 25: 263–70.
   PubMed Web of Science ®Google Scholar
• Lipponen PK, Collan Y. Simple quantitation of immunohistochemical staining positivity in microscopy for histopathol-ogy routine. Acta Stereol 1992; 11: 125–32.
   Google Scholar
• Baak JPA, van Dop H, Kurver PH, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374–82.
   PubMed Web of Science ®Google Scholar
• Haapasalo H, Pesonen E, Collan Y. Volume corrected mitotic index (M/V-index). The standard of mitotic activity in neoplasms. Path Res Pract 1989; 185: 551–4.
   PubMed Web of Science ®Google Scholar
• Collan YUI, Kuopio T, Baak JPA, Becker R, Bogomoletz WV, Deverell M, et al. Standardized mitotic counts in breast cancer. Evaluation of the method. Path Res Pract 1996; 92: 931–41.
   Google Scholar
• Kronqvist P, Kuopio T, Conan Y. Morphometric grading in breast cancer: Thresholds for mitotic counts. Hum Pathol 1998; 29: 1462–8.
   PubMedGoogle Scholar
• Norton E. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999; 26(1 Suppl 2): 11–20.
   PubMedGoogle Scholar
• Base1ga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–44.
   PubMedGoogle Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–48.
   PubMed Web of Science ®Google Scholar
• Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63–72.
   PubMed Web of Science ®Google Scholar
• Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and imminohistochemistry. J Clin Oncol 2000; 18: 3651–64.
   PubMed Web of Science ®Google Scholar
• Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immu-nohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 1999; 17: 1974–82.
   Google Scholar
• Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191–8.
   PubMed Web of Science ®Google Scholar
• Hurlimann J, Larrinaga B, Vala D. Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995; 426: 163–8.
   PubMedGoogle Scholar
• Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72: 354–60.
   PubMedGoogle Scholar
• Nakopoulou L, Michalopoulou A, Giannopoulou I, Tzonou A, Keramopoulos A, Lazaris AC, et al. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immonostain-ing. Histopathology 1999; 34: 310–9.
   PubMedGoogle Scholar
• Holmqvist P, Lundstrom M, Stal O. Apoptosis and bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer. South-East Sweden Breast Cancer Group. Int J Biol Markers 1999; 14: 84–91.
   PubMedGoogle Scholar
• Villar E, Redondo M, Rodrigo I, Garcia J, Avila E, Matilla A. bcl-2 Expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol 2001; 22: 137–45.
   PubMedGoogle Scholar
• Le MG, Mathieu MC, Douc-Rasy S, Le-Bihan ML, AdB-H, Spiehnann M, et al. c-myc, p53, and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999; 84: 562–7.
   PubMed Web of Science ®Google Scholar
• McLaughlin R, O'Hanlon D, McHale T, Connolly CE, Given HE Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer. Ir J Med Sci 2001; 170: 11–3.
   PubMedGoogle Scholar
• Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncol-ogy Group Study. Clin Cancer Res 1998; 4: 7–12.
   PubMed Web of Science ®Google Scholar
• Wald DJ, Chamberlain J, Hackshaw A. European Society of Mastology consensus conference on breast cancer screening—report of the evaluation committee. Br J Radiol 1994; 67: 925–33.
   PubMedGoogle Scholar